Brady Clark, Ph.D.
Chief Executive Officer (CEO) & Founder
Dr. Clark is CEO and founder of Sussex Research Laboratories Inc. He is a leading specialist in the applications of carbohydrates to drug and vaccine discovery and development. Dr. Clark has broad experience working with researchers based in academia and companies in the biotech, pharma and branded life sciences space. As CEO, Dr. Clark develops client technical and business relationships while conceiving and overseeing developmental strategies to commercialize carbohydrate synthesis technologies, products and CRO/CDMO services. He continuously pursues different opportunities in order to advance the company’s position as a leading specialist in carbohydrate drug discovery and development. Prior to founding Sussex Research Laboratories Inc., Dr. Clark was a Researcher at the National Research Council (NRC) of Canada. He has over 30 peer-reviewed science publications and has patents in Canada, U.S., Europe, China and Japan. Dr. Clark received a Doctorate in Chemistry from McMaster University (Canada).
Fengyang Yan, Ph.D.
Vice-President of Chemistry (VP)
As VP of Chemistry, Dr. Yan leads the company’s various programs for development of synthetic strategies of glycosylated molecules and glycoconjugates. He oversees the development of synthetic methodologies designed to access carbohydrate-based molecules using classic solution phase chemistry and chemoenzymatic synthesis. Prior to joining Sussex Research Laboratories Inc., Dr. Yan was a Researcher at the National Research Council (NRC) of Canada. Dr. Yan received a Doctorate in Chemistry from Okayama University (Japan).
Remmick So, M.Sc.
Chief Operating Officer (COO) & Project Manager (PM)
Ms. So manages all synthetic chemistry projects and operational functions while cultivating and communicating policies to employees. She also oversees product quality assurance, identifies systems inefficiencies and designs and implements operations strategies. Ms. So joined the company in 2013 as a Research Biochemist and played an instrumental role in the development of GlycolastinTM, the company’s cosmetic glycopeptide, patented in Canada, U.S., Europe, China and Japan. As Bioanalytical Team Lead within the Vaccine Division, Ms. So helped develop a broad-spectrum pneumococcal conjugate vaccine (PCV) for pre-clinical studies. Prior to joining Sussex Research Laboratories Inc., Ms. So held positions at PharmaGap Inc., VBI Vaccines Inc., the National Research Council (NRC) of Canada and Liponex Inc. Ms. So received a B.Sc. in Computational Chemistry and M.Sc. in Biology from Carleton University (Canada).
Dennis Whitfield, Ph.D.
Chief Scientific Officer (CSO)
Dr. Whitfield joined the company in 2017 and is responsible for overseeing development of new synthetic strategies for development of future products relating to biological ligands and vaccine design. Prior to joining Sussex Research Laboratories Inc., Dr. Whitfield enjoyed a long career with the National Research Council (NRC) of Canada, Division of Immunochemistry, Institute of Biological Sciences where he was Group Leader of carbohydrate synthesis. His group synthesized β-glucan derivatives, bacterial carbohydrate antigens, glycolipid adjuvants, bacterial nonulosonic acids and performed detailed mechanistic studies of the glycosylation reaction mechanism. Previous roles included Research Associate positions within the Department of Medical Genetics (University of Toronto) and Hospital for Sick Children (Toronto) where he developed polymer supported solution synthesis of oligosaccharides and discovered heparin fragments that bind heavy metals in human kidneys, respectively. Dr. Whitfield received a Doctorate in Chemistry from the University of Victoria (Canada).
Glycopeptides / Conjugates
OPERATIONS & FINANCE
Sales & Inquiries
Quotes, Documents & Technical Information
Products, Services & Custom Synthesis
Logistics, Customs & Tracking Information
Accounts & Invoices/Billing